Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated